Theranostic tumor homing nanocarriers for the treatment of lung cancer

Nanoparticles conjugated with 6His-PEG2000-CREKA through DOGS-Ni-NTA for targeting tumor vasculature (PCNCs-D) by (i) intravenous administration bind to the (ii) clotted plasma proteins on tumor blood vessels and (iii) release the payload. In-Vivo Imaging of (A) tumor bearing mouse with (B) PCNCs-Di targeting reveals tumor vasculature and 30-60 fold enhanced delivery of payload carried by nanoparticle compared to non-targeted nanoparticle (C) NCs-Di.99